Story
FactSet Shares Rise After Q4 Earnings Beat, AI Products Drive Growth

Summary
FactSet Research Systems reported fiscal fourth-quarter results that surpassed analyst expectations, driven by strong client demand and early success in monetizing its artificial intelligence offerings. The financial data provider's stock gained following the announcement, despite guiding for a slight slowdown in growth for the upcoming fiscal year.
FactSet Research Systems (NYSE: FDS) reported fiscal fourth-quarter earnings and revenue that exceeded analyst estimates, capping a year of consistent growth and sending its shares up nearly 4% in trading. The results were bolstered by the strongest annual growth in subscription value in three years and tangible evidence that its investments in artificial intelligence are beginning to pay off.
Performance and Outlook
For the quarter ending its fiscal year 2026, FactSet delivered a solid performance that beat management's own guidance across key metrics. The company also provided its outlook for the upcoming fiscal year, signaling continued but more moderate growth.
- Adjusted EPS: $4.52, beating the consensus estimate of $4.35.
- Revenue: $635.5 million, slightly ahead of the $629.7 million estimate.
- Organic Annual Subscription Value (ASV): Grew by 7.0% year-over-year to $2.56 billion, a critical indicator of future revenue for the subscription-based business.
- FY2027 ASV Guidance: The company guided for organic ASV growth of +5% to +6.5%, a deceleration from the rate achieved in fiscal 2026.
For the full fiscal year 2026, FactSet reported revenue of $2.476 billion, a 6.7% increase, and generated a record $168 million in new organic ASV, up 30% from the prior year. Management described its sales pipeline as being "as robust as a year ago" and attributed the conservative guidance to business patterns weighted toward the second half of the year.
AI Monetization Takes Center Stage
AdIn its earnings call, FactSet management addressed key investor questions, with a significant focus on its artificial intelligence strategy. The company provided concrete data points showing AI is becoming a meaningful revenue driver, not just a narrative.
More than 10% of new ASV in the fourth quarter came directly from AI-enabled products. Furthermore, FactSet noted that clients using its AI offerings are increasing their ASV 50% faster than non-AI clients, signaling a strong potential for upselling and client retention. The company also highlighted its competitive position against rivals like Bloomberg, stating its advantage lies in bundling data with analytics and workflow tools, with over 450 clients now engaged with its Model Context Protocol (MCP) data delivery services.
Market Reaction
Investors reacted positively to the earnings beat and the clear signs of AI monetization, with FactSet's stock rising 3.90% to $270.12 following the report. However, the share price remains about 15% below its 52-week high, reflecting some market caution.
The primary concern for investors is whether the guided slowdown in ASV growth for fiscal 2027 represents a new, lower ceiling or a conservative floor. While the bull case points to five consecutive quarters of accelerating ASV and strong free cash flow of $707 million, the bear case highlights the decelerating guidance and the persistent competitive threat from other data providers.
Read next
More on Stocks
US Transportation Secretary Pushes to Expedite Aircraft Certification Amid China Competition Concerns
Transportation Secretary Sean Duffy stated the U.S. must speed up its aircraft approval process to maintain a competitive edge against China and encourage private investment in aviation innovation. The move follows existing FAA efforts to modernize certification.

Jefferies Identifies Three Biotech Firms with Blockbuster Drug Potential
Investment firm Jefferies has highlighted Delphia Therapeutics, Axsome Therapeutics, and BridgeBio Pharma as undervalued biotech companies with strong late-stage pipelines and significant commercial prospects.

Synopsys Shares Rise on OpenAI Partnership and Strong Revenue Forecast
Chip design software leader Synopsys is partnering with OpenAI on a revenue-sharing basis to develop a specialized AI model for semiconductor design, a move that boosted its stock and financial outlook.

Jefferies Initiates Coverage on Molbio Diagnostics with 'Buy' Rating
Jefferies has initiated coverage on Molbio Diagnostics, naming it a top pick in India's medical supplies sector with a 'Buy' rating and a price target of INR 1,600, citing the strength of its point-of-care diagnostics platform.